Robert J. Gould, born in 1955, is a skilled CEO in the biotech field with a strong educational background, holding a B.A. from Spring Arbor University and a Ph.D. from the University of Iowa. He also completed postdoctoral studies at...

Robert J. Gould, born in 1955, is a skilled CEO in the biotech field with a strong educational background, holding a B.A. from Spring Arbor University and a Ph.D. from the University of Iowa. He also completed postdoctoral studies at Johns Hopkins University, giving him deep insights into biotechnology. Dr. Gould served in various roles at Fulcrum Therapeutics, Inc., including a recent stint as interim CEO from January to July 2023. Throughout his time at Fulcrum, he has overseen important developments and strategy alignments. Although his compensation in recent years has varied, in 2023, he earned $348,097, primarily from his salary as he did not receive bonuses or stock awards during his interim role. This reflects a focus on performance and retention in a competitive industry. Notably, Dr. Gould has actively engaged in insider trading within his company, with transactions peaking at $14.15 million in September 2021. This activity indicates a strong confidence in the company’s future, even as his recent holdings have fluctuated significantly. His background, combined with his experience in a leadership role at Fulcrum, positions him as a key player in driving the company’s growth in the biotech sector.